What did the Clouded Leopards at the Smithsonian National Zoo in Washington D.C. and Millions of Turkey Poults Teach us About our Market Potential?

The market for bacterial vaccines and immuno-therapeutics is projected to grow at the rate of 17% per year¹ with the cost of Staphylococcal infections is currently estimated to be $26 billion. Syntiron’s innovative propriety technology, with proven protective results among diverse animal species, provides a tremendous competitive advantage for developing vaccine products for the prevention of human disease.

Our underlying technology targets highly conserved proteins necessary for bacterial life present on all bacterial species. As a result, our vaccine platform holds remarkable potential for application across a broad spectrum of bacterial diseases for which there are large and growing markets, including hospital-acquired infection, UTIs, wound infection, food contamination, as well as bioterrorism.

Intellectual Property

Syntiron’s technology platform is based on a strategic alliance and exclusive cross-license agreements of patented intellectual property (IP) rights from Epitopix. This strategic alliance gives Syntiron exclusive right to the IP platform necessary to develop the SRP® technology for human health care. The agreement includes access to patented, proprietary technologies for sustained/delayed release vaccine formulation and for overriding maternal immunity in young animals.

This technology is compatible with SRP®-based vaccines, and has been demonstrated to generate very desirable product attributes. Incorporation of these technologies into SRP®-based vaccines will provide exciting “next generation” vaccines and extended product lifecycles.

Safety, Efficacy and Commercial Scalability

Our strategic alliances with the National Institutes of Health (NIH) and the Defense Threat Reduction Agency (DTRA), further validates the impact SRP® technology could have on human health care. Since 2006 they include:

• Four Phase I NIH grants for the research and development of vaccines against Salmonella spp., Staphylococcus aureus, and Yersinia pestis.
• A $4.1 million DTRA contract to explore the application of the technology in the development of a multi-valent vaccine against three major bioterror agents; Anthrax, Burkholderia and Yersinia.
• While the cost of developing and manufacturing SRP® vaccines is relatively low, the expenditures required for FDA approval of a vaccine exceed $700 million.

Staphlyococcus Auras: The $8 Billion Dollar Bacteria

In 2009, Syntiron entered into an exclusive agreement with sanofi pasteur for the development of a vaccine which would protect against Staphylococcus aureus, the most common and costly hospital acquired infection. This strategic alliance will allow us to cross the regulatory hurdle and develop a vaccine whose market potential exceeds $8 billion.

For more information please contact:

Paul Treiber
Syntiron LLC
Phone : +651-641-2876
Fax: +651-641-2877

NOTES

1. Global Vaccine Market Outlook (2007-2010). RNCOS E-Services Pvt. Ltd.: Delhi, India, November 2007